Antunes Mariana A, Abreu Soraia C, Cruz Fernanda F, Teixeira Ana Clara, Lopes-Pacheco Miquéias, Bandeira Elga, Olsen Priscilla C, Diaz Bruno L, Takyia Christina M, Freitas Isalira P R G, Rocha Nazareth N, Capelozzi Vera L, Xisto Débora G, Weiss Daniel J, Morales Marcelo M, Rocco Patricia R M
Respir Res. 2014 Oct 3;15(1):118. doi: 10.1186/s12931-014-0118-x.
We sought to assess whether the effects of mesenchymal stromal cells (MSC) on lung inflammation and remodeling in experimental emphysema would differ according to MSC source and administration route. Emphysema was induced in C57BL/6 mice by intratracheal (IT) administration of porcine pancreatic elastase (0.1 UI) weekly for 1 month. After the last elastase instillation, saline or MSCs (1×105), isolated from either mouse bone marrow (BM), adipose tissue (AD) or lung tissue (L), were administered intravenously (IV) or IT. After 1 week, mice were euthanized. Regardless of administration route, MSCs from each source yielded: 1) decreased mean linear intercept, neutrophil infiltration, and cell apoptosis; 2) increased elastic fiber content; 3) reduced alveolar epithelial and endothelial cell damage; and 4) decreased keratinocyte-derived chemokine (KC, a mouse analog of interleukin-8) and transforming growth factor-β levels in lung tissue. In contrast with IV, IT MSC administration further reduced alveolar hyperinflation (BM-MSC) and collagen fiber content (BM-MSC and L-MSC). Intravenous administration of BM- and AD-MSCs reduced the number of M1 macrophages and pulmonary hypertension on echocardiography, while increasing vascular endothelial growth factor. Only BM-MSCs (IV > IT) increased the number of M2 macrophages. In conclusion, different MSC sources and administration routes variably reduced elastase-induced lung damage, but IV administration of BM-MSCs resulted in better cardiovascular function and change of the macrophage phenotype from M1 to M2.
我们试图评估间充质基质细胞(MSC)对实验性肺气肿中肺部炎症和重塑的影响是否会因MSC来源和给药途径而异。通过每周气管内(IT)给予猪胰弹性蛋白酶(0.1 UI),持续1个月,在C57BL/6小鼠中诱导肺气肿。在最后一次弹性蛋白酶滴注后,将从小鼠骨髓(BM)、脂肪组织(AD)或肺组织(L)分离的生理盐水或MSC(1×105)静脉内(IV)或经气管内给药。1周后,对小鼠实施安乐死。无论给药途径如何,每种来源的MSC均产生:1)平均线性截距降低、中性粒细胞浸润和细胞凋亡减少;2)弹性纤维含量增加;3)肺泡上皮和内皮细胞损伤减轻;4)肺组织中角质形成细胞衍生趋化因子(KC,白细胞介素-8的小鼠类似物)和转化生长因子-β水平降低。与静脉内给药相比,经气管内给予MSC进一步减轻了肺泡过度充气(BM-MSC)和胶原纤维含量(BM-MSC和L-MSC)。静脉内给予BM-和AD-MSCs减少了M1巨噬细胞数量和超声心动图检测到的肺动脉高压,同时增加了血管内皮生长因子。只有BM-MSCs(静脉内给药>经气管内给药)增加了M2巨噬细胞数量。总之,不同的MSC来源和给药途径可不同程度地减轻弹性蛋白酶诱导的肺损伤,但静脉内给予BM-MSCs可带来更好的心血管功能,并使巨噬细胞表型从M1转变为M2。